Multiple studies have conducted prospective clinical trials focused on imatinib withdrawal in CML patients, where the levels of BCR-ABL1 in the peripheral blood were closely monitored by polymerase chain reaction (PCR). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.